2010年12月2日 · CYP3A4 is the most abundant detoxifying enzyme in the liver, and is responsible for helping to break down perhaps 60% of all known drugs. It also has an important role in the breakdown of testosterone.

2011年3月17日 · Our study aimed to comprehensively investigate the genetic polymorphisms of CYP3A4 in Han Chinese. We sequenced the gene regions of CYP3A4, including its promoter, exons, surrounding introns...

In this review we summarize CYP3A4 pharmacogenetics/genomics from the early inheritance estimations up to the most recent genetic and clinical studies, including new findings about SNPs in CYP3A4 (*22) and other genes (P450 oxidoreductase (POR), peroxisome proliferator-activated receptor alpha (PPARA)) with possible contribution to CYP3A4 ...

Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile. 2013 2

Large interperson variability in CYP3A4 activity affects response to CYP3A4 substrate drugs. We had demonstrated that an intronic single nucleotide polymorphism (SNP) rs35599367 (CYP3A4*22, located in intron 6) reduces mRNA/protein expression

Cytochrome P450 3A4 (CYP3A4) metabolizes 30-50% of clinically used drugs. Large interperson variability in CYP3A4 activity affects response to CYP3A4 substrate drugs. We had demonstrated that an intronic single nucleotide polymorphism rs35599367 (CYP3A4*22, located in intron 6) reduces mRNA/protein …

A new CYP3A4 allele (CYP3A4*22; rs35599367 C>T in intron 6) with a frequency of 5-7% in the Caucasian population was recently discovered through its association with low hepatic CYP3A4 expression and CYP3A4 activity, and showing effects on …

2014年7月2日 · Among twenty HIV-positive patients undergoing LPV/r monotherapy enrolled in this study, CYP3A4*1B was found in two patients with treatment failure and decreased TDM of LPV. These data may suggest that the presence of CYP3A4 SNPs, in particular the CYP3A4*1B variant, may have a role in reducing LPV efficacy.

2021年7月8日 · However, the recent discovery of the intron 6 single-nucleotide polymorphism (SNP) rs35599367C > T, encoding the CYP3A4∗22 allele, led to several studies into the pharmacogenetic effect of CYP3A4∗22 on different drugs. This allele has a relatively minor allele frequency of 3-5% and an effect on CYP3A4 enzymatic activity.

在临床药代动力学试验中发现了一个巴西血统的异常值，该值显示比研究药物的预期暴露高6倍，该研究药物为CYP3A4底物。 我们旨在调查这一发现的遗传背景。 方法对异常基因CYP3A4的等位基因变异进行测序，并在酵母和人胚肾细胞中表达相应的互补脱氧核糖核酸。 通过静脉内给药1mg咪达唑仑对异常值进行表型分析。 表型和基因型的相关性进行了分析。 在白人人群中筛选了新等位基因的患病率。 结果我们确定了一个杂合了一个新的CYP3A4等位基因的受试者，名 …